10-Q: Eli Lilly's Q2 Revenue Soars 48% on Mounjaro, Zepbound Strength

Eli Lilly and Company reported a significant 48% increase in revenue for the second quarter of 2026, driven by strong performance in its cardiometabolic health products, particularly Mounjaro and Zepbound.

Summary

• Eli Lilly and Company reported a substantial 48% increase in revenue for the three months ended June 30, 2026, reaching $22.974 billion, compared to $15.558 billion in the prior year period.
• Net income for the quarter rose by 25% to $7.095 billion, with diluted earnings per share increasing to $7.94 from $6.29.
• For the six months ended June 30, 2026, revenue grew by 51% to $42.773 billion, and net income increased by 72% to $14.491 billion, with diluted EPS at $16.19.
• The strong performance was primarily attributed to increased volume from Mounjaro and Zepbound, although partially offset by lower realized prices.
• Acquired in-process research and development (IPR&D) charges significantly increased to $2.776 billion for the quarter and $3.360 billion for the six months, impacting profitability.
• The company completed several significant acquisitions in the first half of 2026, including Kelonia Therapeutics, Centessa Pharmaceuticals, and Ventyx Biosciences, with further acquisitions planned.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strongly positive filing, driven by exceptional revenue growth and robust net income increases, largely fueled by the success of key products like Mounjaro and Zepbound.

Positives

• Exceptional revenue growth of 48% for the quarter and 51% for the six months, driven by strong volume increases in key products.
• Significant increase in net income by 25% for the quarter and 72% for the six months, demonstrating strong operational leverage.
• Diluted earnings per share saw a substantial increase of 26% for the quarter and 73% for the six months.
• Gross margin improved to 85.8% for the quarter and 84.0% for the six months, indicating better cost of production and favorable product mix.
• Mounjaro and Zepbound continue to be major growth drivers, with Mounjaro revenue up 91% and Zepbound up 46% for the quarter.
• The company is actively investing in its future through significant R&D spending and strategic acquisitions.
• Cash and cash equivalents increased to $9.0 billion, providing strong liquidity.

Negatives

• Acquired in-process research and development (IPR&D) charges increased significantly, impacting net income.
• Asset impairment, restructuring, and other special charges also saw a substantial increase.
• Effective tax rate increased to 23.3% for the quarter and 19.9% for the six months, partly due to nondeductible IPR&D charges.
• Lower realized prices for key products like Zepbound and Mounjaro, though offset by volume and rebate adjustments.
• Significant debt increase to $54.9 billion, up $12.4 billion from the prior year-end, primarily due to financing acquisitions.

Risks

• Intense competition affecting products, pipeline, and the industry.
• Continued pricing pressures and actions by governmental and private actors affecting pricing, reimbursement, and patient access.
• Dependence on a few products for a significant percentage of total revenue.
• Expiration of intellectual property protection and competition from generic and biosimilar products.
• Potential for litigation, investigations, and other proceedings involving past, current, or future products and activities.
• Regulatory changes, developments, and uncertainty, including compliance issues and government investigations.
• Risks associated with the use of artificial intelligence and other emerging technologies.
• Global macroeconomic conditions, including uneven economic growth, trade disputes, and international tensions.

Future Outlook

The company anticipates its near-term financial performance will be impacted by the timing of potential regulatory approvals for orforglipron, as well as demand and uptake in new incretin channels and markets, including U.S. Medicare for Zepbound and Foundayo. Longer term, sustained growth depends on maintaining a competitive position and delivering further innovations.

Management Comments

• Revenue increased for the three and six months ended June 30, 2026, driven primarily by increased volume, partially offset by lower realized prices. The increased volume and the lower realized prices during the three and six months ended June 30, 2026 were primarily driven by Mounjaro and Zepbound.
• Net income and earnings per share for the three months ended June 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, asset impairment, restructuring, and other special charges, and marketing, selling, and administrative expenses.
• Net income and earnings per share for the six months ended June 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, research and development expenses, and marketing, selling, and administrative expenses.

Industry Context

StockSavvy.ai notes that Eli Lilly's performance aligns with broader trends in the pharmaceutical industry, particularly the significant growth in the obesity and diabetes treatment markets driven by innovative therapies like GLP-1 receptor agonists. The company's strategic acquisitions also reflect an industry-wide trend of consolidation and investment in promising new technologies.

Comparison to Industry Standards

• Eli Lilly's revenue growth of 48% for the quarter significantly outpaces the average revenue growth for large pharmaceutical companies, which typically ranges from low to mid-single digits.
• The company's net income growth of 72% for the six-month period is exceptionally strong, far exceeding industry averages, indicating superior operational efficiency and product success.
• The substantial investment in acquired IPR&D, totaling $3.36 billion for the six months, highlights a proactive strategy to bolster the pipeline, a common practice among leading pharmaceutical firms aiming for sustained innovation.
• The effective tax rate of 19.9% for the six-month period is within the typical range for large pharmaceutical companies operating in multiple tax jurisdictions, though the increase from the prior year is noted.

Legal Proceedings

• Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. lawsuit regarding Emgality patent infringement, with ongoing appeals.
• Cipla Ltd. and Cipla USA Inc. patent infringement action regarding Verzenio.
• Multiple generic companies filing ANDAs for generic versions of Mounjaro and/or Zepbound, with intent to file patent infringement suits.
• Ongoing Superfund matters related to environmental cleanup.
• Brazil Litigation: Cosmopolis Facility Labor Attorney Litigation with ongoing appeals.
• 340B Litigation and Investigations, including lawsuits challenging contract pharmacy policies and pricing.
• Insulin Pricing Litigation, with ongoing proceedings in multidistrict litigation and state courts.
• Various investigations and inquiries from governmental entities related to drug pricing and sales.
• Actos Litigation: third-party payer class action alleging concealment of bladder cancer risk.
• Mounjaro, Trulicity, and Zepbound Product Liability Litigation, coordinated in federal MDLs for alleged gastrointestinal injuries and NAION.
• Health Choice Alliance qui tam lawsuit related to patient support programs.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and net income growth, and increased EPS. Continued share repurchases and dividend payments also benefit shareholders.
• Employees: Potential impact from acquisition and integration costs, as well as ongoing R&D investments. Stock-based compensation is a component of equity.
• Customers (Patients): Increased access to key medications like Mounjaro and Zepbound, with potential for expanded access through programs like the Medicare GLP-1 Bridge Program. However, pricing pressures and access challenges remain a concern.
• Suppliers: Increased demand for products may lead to greater business opportunities for suppliers, but also potential pressure on pricing and supply chain management.
• Creditors: Increased debt levels may impact credit metrics, though strong cash flow generation provides a buffer.

Next Steps

• Continue to monitor demand and uptake for incretin medicines in new channels and markets, including U.S. Medicare for Zepbound and Foundayo.
• Operationalize additional manufacturing capacity over the next several years to support anticipated demand.
• Continue to engage with regulatory bodies and healthcare providers regarding pricing, reimbursement, and access for key products.
• Integrate recent acquisitions (Kelonia, Centessa, Ventyx) and pursue planned acquisitions, such as AtaiBeckley Inc.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with significant revenue and profit growth driven by blockbuster drugs. Strategic acquisitions and a robust pipeline further support long-term growth prospects, outweighing concerns about increased R&D and debt financing for acquisitions.

Keywords

pharmaceuticals, Mounjaro, Zepbound, revenue growth, net income, acquisitions, R&D, Cardiometabolic Health